Skip to main content
. 2020 Aug 3;99:84–91. doi: 10.1016/j.ijid.2020.07.053

Table 3.

Analysis for time to SARS-CoV-2 clearance.

p-value
Novaferon LPV/ra + Novaferon LPV/r LPV/r vs. Novaferon LPV/r vs. LPV/r + Novaferon Novaferon vs. LPV/r + Novaferon
N (Censored) 30 (13) 30 (9) 29 (14)
Mean (days) 7.0 6.1 8.0
Median (days)b 6 6 9 0.417 0.036 0.183
a

LPV/r: Lopinavir/Ritonavir.

b

Median time for each group was estimated with the use of the Kaplan–Meier method and treatment differences were tested using the log-rank test.